RxDoctor Payments Data

Robert Collins

Rheumatology · Nashville, TNNPI 1851474092

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.9% of the total across 347 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for rheumatology clinicians in TN, where the typical reported total is $5,288.

$5,251in general payments, 2019–2025

Across 347 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • AbbVie$1K
  • Novartis$795
  • Amgen$689
  • Lilly USA, LLC$319
  • GSK$280
  • plus $953 from 12 others
$377,582in research payments, 2019–2025

Across 192 payments — averaging $1966.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$369K
  • Novartis$4K
  • Eli Lilly$4K
  • Ironwood Pharmaceuticals, Inc$2K

What the payments were for

  • Food & beverage$5,14298%
  • Education$1092%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,251 in reported general payments places this provider in the 45th percentile of 127 rheumatology providers in Tennessee.

See all rheumatology providers in Tennessee

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$241,051
RinvoqUpadacitinib28$178,147
RasuvoMethotrexate/Pf15$10,214
Hydroxychloroquine Sulfate153$7,016
Leflunomide67$5,802
Colchicine30$4,106
MethotrexateMethotrexate Sodium154$3,835
Celecoxib35$3,598
Prednisone127$980
Duloxetine Hcl40$967
Allopurinol36$577
Sulfasalazine15$457
Methotrexate SodiumMethotrexate Sodium/Pf22$319
Alendronate Sodium38$244
Nabumetone14$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,015$178,14728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 127 rheumatology providers in Tennessee.

Other rheumatology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →